Patent Board Grants Inter Partes Review Of Arthritis Treatment Patent
ALEXANDRIA, Va. — A patented method of treating rheumatoid arthritis with anti-tumor necrosis factor α (anti-TNFα) combined with the anti-rheumatic drug methotrexate (MTX) is likely invalid, the Patent Trial and Appeal...To view the full article, register now.
Already a subscriber? Click here to view full article